

# Telmisartan randomised assessment study in ACE intolerant subjects with cardiovascular disease

<b>Submission date</b> 18/12/2002	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 18/12/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/03/2016	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Salim Yusuf

### Contact details

Population Health Research Institute  
McMaster University  
Hamilton General Hospital  
McMaster Clinic  
237 Barton St E  
Hamilton  
Canada  
Ontario L8L 2X2  
+1 (0)905 527 4322 ext 44515  
yusufs@mcmaster.ca

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00153101

**Secondary identifying numbers**

N/A

## Study information

**Scientific Title**

Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

**Acronym**

TRANSCEND

**Study objectives**

This parallel trial to ISRCTN16228603 (ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial = ONTARGET) is to determine in angiotensin converting enzyme inhibitor (ACE-I) intolerant patients if telmisartan 80 mg daily is superior to placebo in reducing the composite endpoint of cardiovascular death, myocardial infarction (MI), stroke or hospitalisation for congestive heart failure (CHF).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Congestive heart failure

**Interventions**

Telmisartan (an angiotensin II blocker) or matched placebo.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Telmisartan

**Primary outcome measure**

1. Cardiovascular death
2. Non-fatal myocardial infarction
3. Non-fatal stroke
4. Hospitalisation for congestive heart failure

**Secondary outcome measures**

1. Newly diagnosed congestive heart failure
2. Cardiovascular revascularisation procedures
3. Newly diagnosed diabetes
4. Cognitive decline (adjudication will be done by a special committee)
5. New onset of atrial fibrillation
6. Nephropathy

**Overall study start date**

01/01/2004

**Completion date**

01/01/2008

**Eligibility****Key inclusion criteria**

1. Adults greater than or equal to 55 years
2. With a history of symptomatic coronary artery disease, cerebrovascular disease, peripheral vascular disease, or diabetes mellitus
3. Without proteinuria
4. Who are intolerant of ACE inhibitors

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

6000

**Key exclusion criteria**

Does not comply with the above criteria

**Date of first enrolment**

01/01/2004

**Date of final enrolment**

01/01/2008

## **Locations**

**Countries of recruitment**

Australia

Austria

Belgium

Canada

China

Czech Republic

Denmark

Finland

France

Germany

Greece

Hong Kong

Hungary

Ireland

Italy

Korea, South

Malaysia

Mexico

Netherlands

New Zealand

Norway

Philippines

Poland

Portugal

Puerto Rico

Russian Federation

Singapore

Slovakia

South Africa

Spain

Sweden

Switzerland

Taiwan

Thailand

Türkiye

Ukraine

United Arab Emirates

United Kingdom

United States of America

**Study participating centre**  
**Hamilton General Hospital**  
Hamilton  
Canada  
Ontario L8L 2X2

**Sponsor information**

**Organisation**

Boehringer Ingelheim (Canada) Ltd

**Sponsor details**

Research and Development

2100 Cunard Street

Laval (Québec)

Canada

H7S 2G5

+1 (0)450 682 4640

info@lav.boehringer-ingelheim.com

**Sponsor type**

Industry

**Website**

<http://www.boehringer-ingelheim.ca/>

**ROR**

<https://ror.org/031sxg258>

**Funder(s)****Funder type**

Industry

**Funder Name**

Boehringer Ingelheim (Canada) Ltd

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>				No	No

<a href="#">Protocol article</a>	protocol	01/07/2004	Yes	No
<a href="#">Other publications</a>	baseline data	01/04/2005	Yes	No
<a href="#">Results article</a>	results	20/03/2007	Yes	No
<a href="#">Results article</a>	results	27/09/2008	Yes	No
<a href="#">Results article</a>	results	06/10/2009	Yes	No
<a href="#">Results article</a>	results	30/03/2010	Yes	No